AstraZeneca and Merck & Co., Inc. announced the European Commission has approved jointly developed Lynparza as a treatment of adult patients with a type of metastatic breast cancer.
Dave Fredrickson, executive vice President, oncology, said: “With this approval, Lynparza provides patients throughout the EU with a targeted and oral chemotherapy-free treatment option for a difficult-to-treat cancer. It also reinforces the importance of testing for biomarkers including BRCA, hormone receptor and HER2 expression, helping physicians to make the most informed treatment decisions for patients.”
The approval was based on data from the open-label, Phase III OlympiAD trial which tested Lynparza vs. physician’s choice of chemotherapy.
This is the third indication for Lynparza in the European Union and AstraZeneca and Merck are working together to deliver Lynparza as quickly as possible to more patients across multiple settings.
